Since cemiplimab was approved by United States Food and Drug Administration in 2018,anti-programmed cell death receptor-1 antibodies have been considered as the first-line systemic therapy for advanced cutaneous squamous cell carcinoma.This review focuses on current clinical application of targeted therapy,immunotherapy,targeted immunotherapy and gene therapy for cutaneous squamous cell carcinoma.
NETL
NSTL
万方数据
